BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spyrou N, Vallianou N, Kadillari J, Dalamaga M. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. Seminars in Cancer Biology 2021;73:356-76. [DOI: 10.1016/j.semcancer.2021.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Vallianou N, Kounatidis D, Christodoulatos GS, Panagopoulos F, Karampela I, Dalamaga M. Mycobiome and Cancer: What Is the Evidence? Cancers (Basel) 2021;13:3149. [PMID: 34202433 DOI: 10.3390/cancers13133149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Stirling ER, Bronson SM, Mackert JD, Cook KL, Triozzi PL, Soto-Pantoja DR. Metabolic Implications of Immune Checkpoint Proteins in Cancer. Cells 2022;11:179. [PMID: 35011741 DOI: 10.3390/cells11010179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang X, Li H, Lv X, Hu L, Li W, Zi M, He Y. Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors. Life 2022;12:409. [DOI: 10.3390/life12030409] [Reference Citation Analysis]
4 Dalamaga M, Zheng L, Liu J. Gut mycobiome as a promising preventive and therapeutic target for metabolic disorders. Metabolism Open 2022;13:100168. [DOI: 10.1016/j.metop.2022.100168] [Reference Citation Analysis]
5 Laudes M, Geisler C, Rohmann N, Bouwman J, Pischon T, Schlicht K. Microbiota in Health and Disease-Potential Clinical Applications. Nutrients 2021;13:3866. [PMID: 34836121 DOI: 10.3390/nu13113866] [Reference Citation Analysis]
6 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
7 Fotis D, Liu J, Dalamaga M. Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives. Metabolism Open 2022;14:100178. [DOI: 10.1016/j.metop.2022.100178] [Reference Citation Analysis]
8 Christodoulatos GS, Antonakos G, Karampela I, Psallida S, Stratigou T, Vallianou N, Lekka A, Marinou I, Vogiatzakis E, Kokoris S, Papavassiliou AG, Dalamaga M. Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study. Biomolecules 2021;11:1609. [PMID: 34827610 DOI: 10.3390/biom11111609] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Moos WH, Faller DV, Glavas IP, Harpp DN, Kamperi N, Kanara I, Kodukula K, Mavrakis AN, Pernokas J, Pernokas M, Pinkert CA, Powers WR, Steliou K, Tamvakopoulos C, Vavvas DG, Zamboni RJ, Sampani K. Pathogenic mitochondrial dysfunction and metabolic abnormalities. Biochem Pharmacol 2021;193:114809. [PMID: 34673016 DOI: 10.1016/j.bcp.2021.114809] [Reference Citation Analysis]
10 Farràs M, Escolà-Gil JC. Special issue: Diet, lipids, and cancer: From Pathogenic mechanisms to potential therapeutic strategies. Semin Cancer Biol 2021;73:1-3. [PMID: 34015466 DOI: 10.1016/j.semcancer.2021.05.015] [Reference Citation Analysis]